AU2013356792A1 - Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-DS-Mal-III - Google Patents

Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-DS-Mal-III Download PDF

Info

Publication number
AU2013356792A1
AU2013356792A1 AU2013356792A AU2013356792A AU2013356792A1 AU 2013356792 A1 AU2013356792 A1 AU 2013356792A1 AU 2013356792 A AU2013356792 A AU 2013356792A AU 2013356792 A AU2013356792 A AU 2013356792A AU 2013356792 A1 AU2013356792 A1 AU 2013356792A1
Authority
AU
Australia
Prior art keywords
ppi
mal
iii
dendrimer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013356792A
Other languages
English (en)
Inventor
Dietmar Appelhans
Maria BRYSZEWSKA
Ida FRANIAK-PIETRYGA
Barbara KLAJNERT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Łódź
Original Assignee
LODZKI, University of
University of Łódź
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LODZKI, University of, University of Łódź filed Critical LODZKI, University of
Publication of AU2013356792A1 publication Critical patent/AU2013356792A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2013356792A 2012-12-06 2013-12-03 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-DS-Mal-III Abandoned AU2013356792A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PLP.401934 2012-12-06
PL401934A PL234887B1 (pl) 2012-12-06 2012-12-06 Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-DS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej
PCT/PL2013/000154 WO2014088434A1 (en) 2012-12-06 2013-12-03 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii

Publications (1)

Publication Number Publication Date
AU2013356792A1 true AU2013356792A1 (en) 2015-07-23

Family

ID=49955471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013356792A Abandoned AU2013356792A1 (en) 2012-12-06 2013-12-03 Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-DS-Mal-III

Country Status (9)

Country Link
US (1) US20150320692A1 (cg-RX-API-DMAC10.html)
EP (1) EP2928478A1 (cg-RX-API-DMAC10.html)
JP (1) JP2016501260A (cg-RX-API-DMAC10.html)
KR (1) KR20150099539A (cg-RX-API-DMAC10.html)
AU (1) AU2013356792A1 (cg-RX-API-DMAC10.html)
CA (1) CA2896673A1 (cg-RX-API-DMAC10.html)
IL (1) IL239143A0 (cg-RX-API-DMAC10.html)
PL (1) PL234887B1 (cg-RX-API-DMAC10.html)
WO (1) WO2014088434A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL234888B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208580A1 (en) * 2005-09-19 2009-08-20 Regents Of The University Of Michigan Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles
US20110177602A1 (en) * 2007-06-27 2011-07-21 Endress + Hauser Conducts Gesellschaft furMess-und Regeltechnik mbH +Co. KG Composite Structure
PL234888B1 (pl) * 2012-12-06 2020-04-30 Univ Lodzki Dendrymer polipropylenoiminowy czwartej generacji opłaszczony maltotriozą PPI-G4-OS-Mal-III do zastosowania w leczeniu przewlekłej białaczki limfocytowej

Also Published As

Publication number Publication date
JP2016501260A (ja) 2016-01-18
PL234887B1 (pl) 2020-04-30
EP2928478A1 (en) 2015-10-14
US20150320692A1 (en) 2015-11-12
KR20150099539A (ko) 2015-08-31
IL239143A0 (en) 2015-07-30
CA2896673A1 (en) 2014-06-12
PL401934A1 (pl) 2014-06-09
WO2014088434A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
Feng et al. Mitochondria-associated ER stress evokes immunogenic cell death through the ROS-PERK-eIF2α pathway under PTT/CDT combined therapy
Zhao et al. Sonodynamic therapy of NRP2 monoclonal antibody‐guided MOFs@ COF targeted disruption of mitochondrial and endoplasmic reticulum homeostasis to induce autophagy‐dependent ferroptosis
Xu et al. Rationally designed rapamycin-encapsulated ZIF-8 nanosystem for overcoming chemotherapy resistance
Liu et al. Endothelial cells dysfunction induced by silica nanoparticles through oxidative stress via JNK/P53 and NF-κB pathways
Hsin et al. The apoptotic effect of nanosilver is mediated by a ROS-and JNK-dependent mechanism involving the mitochondrial pathway in NIH3T3 cells
Zhang et al. Prussian blue/calcium peroxide nanocomposites-mediated tumor cell iron mineralization for treatment of experimental lung adenocarcinoma
Sun et al. Multi‐enzyme activity of MIL‐101 (Fe)‐derived cascade nano‐enzymes for antitumor and antimicrobial therapy
Zanotto-Filho et al. The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma
Ziemba et al. Toxicity and proapoptotic activity of poly (propylene imine) glycodendrimers in vitro: Considering their contrary potential as biocompatible entity and drug molecule in cancer
Ahir et al. Tailored-CuO-nanowire decorated with folic acid mediated coupling of the mitochondrial-ROS generation and miR425-PTEN axis in furnishing potent anti-cancer activity in human triple negative breast carcinoma cells
US9861659B2 (en) Pharmaceutical composition for improving health, cure abnormalities and degenerative disease, achieve anti-aging effect of therapy and therapeutic effect on mammals and method thereof
Yusuf et al. Liposomal encapsulation of silver nanoparticles (AgNP) improved nanoparticle uptake and induced redox imbalance to activate caspase-dependent apoptosis
Mameri et al. Oxidative stress as an underlying mechanism of anticancer drugs cytotoxicity on human red blood cells' membrane
Zhang et al. α-Santalol functionalized chitosan nanoparticles as efficient inhibitors of polo-like kinase in triple negative breast cancer
Ponraj et al. Mitochondrial dysfunction-induced apoptosis in breast carcinoma cells through a pH-dependent intracellular quercetin NDDS of PVPylated-TiO2NPs
Albuz et al. Effects of B2O3 (boron trioxide) on colon cancer cells: our first-step experience and in vitro results
Su et al. Roles of PTEN gene methylation in Se-CQDs induced mitochondrial apoptosis of osteosarcoma cells
Wang et al. Endoplasmic reticulum-mitochondria dual-targeting nanoplatform suppresses cancer stemness and enhances colorectal cancer immunotherapy
US9877985B2 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-MAL-III
Murera et al. Few layer graphene does not affect the function and the autophagic activity of primary lymphocytes
US20150320692A1 (en) Application of maltotriose-coated 4th generation polypropyleneimine dendrimer ppi-g4-ds-mal-iii
Jiang et al. Iterative‐Designed Multifunctional Carbon Dots Nanodrug for Celastrol Loading, Targeting Delivery, and Combination Therapy of Kidney Stones
US10022395B2 (en) Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III
JP2004534001A (ja) 細胞に化学化合物を標的化する方法およびそれに使用する製薬学的組成物
Wibowo et al. Effect of degree of acidity and solvent on structural analysis of 1-(2, 5-dihydroxyphenyl)-3-pyridine-2-yl-propenone and cytotoxic activity on T47D cells

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted